COMP <GO>
VTRS vs ALNY // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Viatris Inc. (NASDAQ) VS. Alnylam Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: VTRS 4
— ALNY 8
■ METRIC PARITY
LAST: $19.04 (-0.86%) • MKT CAP: $21.86B
options-implied-move
—
LAST: $165.00 (-5.17%) • MKT CAP: $22.10B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VTRS VS. ALNY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VTRS | ALNY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 35.20% | 81.80% | -46.60 | ALNY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -8.10% | 21.30% | -29.40 | ALNY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 42.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 8.78% | 2.00% | +6.78 | VTRS | /fcf-yield <GO> |
| Operating Margin | -18.70% | 13.50% | -32.20 | ALNY | /operating-margins <GO> |
| Net Profit Margin | -14.60% | 8.40% | -23.00 | ALNY | /net-margins <GO> |
| Revenue Growth (YoY) | -3.00% | 65.20% | -68.20 | ALNY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.81 | 3.16 | -2.35 | ALNY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | ALNY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 62.5 | 25.8 | +36.70 | VTRS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.00 | +0.15 | VTRS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 62.3x | -29.30 | VTRS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $21.86B | $22.10B | -$236.3M | ALNY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VTRS REV | ALNY REV | VTRS GROSS % | ALNY GROSS % | VTRS FCF | ALNY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $14.25B | $3.71B | 35.2% | 81.8% | $1.94B | $465.4M |
| FY 2024 | $14.69B | $2.25B | 38.3% | 86.4% | $1.98B | -$42.6M |
| FY 2023 | $15.39B | $1.83B | — | — | $2.21B | $21.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VTRS // BETA 1.15
ALNY // BETA 1.00